期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肾脏移植患者中厄他培南和他克莫司的药物相互作用研究 被引量：1

Interaction influence of two drugs after simultaneously taking tacrolimus and ertapenem in renal transplant patients
下载PDF
导出
摘要 目的观察广东地区肾脏移植患者同时服用他克莫司(FK-506)与厄他培南后两种药物的相互作用。方法回顾性评价2013年12例肾脏移植患者的情况,利用全自动免疫化学发光仪分析患者在服用厄他培南前后他克莫司的血药浓度。结果首次服用厄他培南3d后,他克莫司的血药浓度由(7.5±0.34)ng/mL升高到(13.8±0.25)ng/mL(P<0.05),利用药物相互作用可能性量表(DIPS)得出的分数可知,厄他培南与他克莫司在患者体内可能存在某种机制相互作用。结论肾脏移植患者同时使用他克莫司和厄他培南时应及时调整他克莫司的剂量,防止药物中毒。 Objective To observe the interaction of tacrolimus（FK‐506） and ertapenem after simultaneously taking in renal transplant recipients of Guangdong region .Methods Twelve renal transplant recipients in our hospital during 2013 were retrospectively evaluated .The blood drug concentrations of tacrolimus and ertapenem were detected by using the automatic chemoluminescence immunoassay .Results The blood concentration of tacrolimus on 3 d after taking was increased from（7 .5 ± 0 .34）ng/mL to（13 .8 ± 0 .25）ng/mL（P〈 0 .05） .The fraction derived from the drug interaction potential scale indicated that certain mechanism of interaction action and influence of ertapenem and ta‐crolimus existed in the patient′s body .Conclusion In simultaneously using tacrolimus （FK‐506） and ertapenem for kidney transplant patients ,the tacrolimus dose should be timely adjusted for preventing the drug poisoning .
作者 朱春丽 吴家清 李琴 刘东 周结学 蒙善东 申升 郑克立
机构地区 广东省第二人民医院器官移植科
出处 《检验医学与临床》 CAS 2015年第19期2890-2891,2894,共3页 Laboratory Medicine and Clinic
关键词 肾移植 厄他培南 他克莫司 renal transplant tacrolimus ertapenem
分类号 R969.2 [医药卫生—药理学]
  • 相关文献

参考文献11

  • 1李继芳,张翠欣,梁春慧.他克莫司药物相互作用的新进展[J].肝胆外科杂志,2008,16(6):472-476. 被引量：8
  • 2Cunha BA. Ertapenem. A review Of its microbiologic, pharmacokinetic and clinical aspects [J]. Drugs Today (Barc) ,2002,38(3) :195 213.
  • 3Gulbis AM, Culotta KS, Jones RB, et al. Busulfan and metronidazole:an often forgotten but significant drug in- teraction[J]. Ann Pharmacother, 2011,45 (7/8) : 39.
  • 4Hu M, Mak VWL, Tomlinson B. Simvastatin-induced my- opathy, the role of interaction with dihiazem and genetic predisposition[J]. J Clin Pharm Ther, 2011,36 (3) 4:19- 425.
  • 5Mir O, Blanchet B,Goldwasser F. Drug-induced effects on erlotinih metabo[ism[J]. N Engl J Med, 2011,365 (4) 379-380.
  • 6Bhaloo S,Prasad GV. Severe reduction in tacrolimus lev els with rifampin despite multiple cytocb.rome P450 inhib itors:a case report[J]. Transplant Proe, 2003,35(7) 2449-2451.
  • 7Clark CJ, Hawley CM, Mudge DW. Probable tacrolimus toxicity from tibolone co administration in a woman: a case report[J]. J Med Case Rep,2010,4(1) :276.
  • 8Obach RS, Lombardo F,Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug comt)ounds[J]. Drug Metab Dispos, 2008,36(7) :1385-1405.
  • 9Thervet E, Anglicheau D, King B, etal. Impact of cyto- chrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipientsl2[J]. Transplantation,2003,76(8) =1233 1235.
  • 10Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after slatting ertapen em therapy[J]. Pharmacotherapy, 2007, 27 (8): 1202- 1205.

二级参考文献37

  • 1王华光,王鹤尧,龙江.他克莫司临床应用的新进展[J].中国药物应用与监测,2004,1(2):5-7. 被引量：10
  • 2王栋海,钱秀萍,陈代杰.抗真菌药物echinocandins和pneumocandins类的研究进展[J].中国抗生素杂志,2004,29(7):439-442. 被引量：12
  • 3徐芳,翟所迪,胡永芳.他克莫司发生药物相互作用的分子机制[J].中国药学杂志,2007,42(13):965-968. 被引量：16
  • 4Elefante A, Muindi J, West K, et al. Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels [ J ]. Bone Marrow Trans- plant ,2006, 37:781 - 784.
  • 5El-Dahshan K F, Bakr M A, Donia A F, et al. Ketoconazole-Tacrolimus Coadministration in Kidney Transplant Recipients: Two- Year Results of a Prospective Randomized Study [ J ]. Am J Nephrol,2006,26:293 - 298.
  • 6Leather H, Boyette R M, Tian L, et al. Pharmacokinetic Evaluation of the Drug Interaction between Intravenous ltraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic Hematopoietic Stem Ceil Transplant Recipients [ J ]. Biol Blood Marrow Transplant ,2006,12:325 - 334.
  • 7Banerjee R, Leaver N, Lyster H, et al. Coadministration of Itracanazole and Tacrolimus After Thoracic Organ Transplantation [ J ]. Transplant Proc,2001, 33 : 1600 - 1602.
  • 8Shimoeda S, Ohta S, Hikaru Kobayahsi S, et al. Analysis of the Blood Level of Micafungin Involving Patients with Hematological Diseases: New Findings Regarding Combination Therapy with Tacrolimus [ J ]. Biol Pharm Bull,2005, 28 ( 3 ) :477 - 480.
  • 9Kunicki P K, Sobieszczan'ska-Malek M. Pharmacokinetic Interaction Between Tacrolimus and Clarithromycin in a Heart Transplant Patient [ J ]. Ther Drug Monit ,2005 ,27 ( 1 ) : 107 - 108
  • 10Moreno M, Latorre A, Manzanares C, et al. Clinical Management of Tacrolimus Drug Interactions in Renal Transplant Patients [ J ]. Transplant Proc, 1999, 31:2252 - 2253.

共引文献7

同被引文献52

  • 1张鑫,刘志红,郑敬民,陈朝红,唐政,陈劲松,黎磊石.肾移植患者他克莫司血药浓度的影响因素[J].肾脏病与透析肾移植杂志,2005,14(4):333-338. 被引量：21
  • 2Kidney Disease: Improving Global Outcomes (KDIGO)Transplant Work Group. KDIGO clinical practice guideline forthe care of kidney transplant recipients[J]. Am J Transplant, 2009, 9(Suppi 3): S1-S155.
  • 3Velickovi6-Radovanovi6 R, Mikov M, Paunovi6 G, et al. Gender differences in pharmacokinetics of tacfolimus and their clinical significance in kidney transplant recipients[J].Gend Med, 2011, 8(1):23-31.
  • 4Ran~i6 N, Dragojevi6-Simi6 V, Vavi6 N, et al. Tacrolimus concentration/dose ratio as a therapeutic drug monitoring strategy: the influence of gender and comedication[J].Vojnosanit Pregl, 2015,72(9):813-822.
  • 5Rodrigo E, de Cos M A, S~inchez B, et all High initial blood levels of taeroUmus in overweight renal transplant recipients[J].Transplant Proc, 2005, 37(3): 1453-1454.
  • 6Hustert E, Haberl M, Burk O, et al. Thegenetic determinants of the CYP3A5 polymorphism[J]. Pharmacogenetics, 2001, 11(9): 773-779.
  • 7Xie H E, Wood A J, Kim R B, et al. Genetic variability in CYP3A5 and its possible consequences[J]. Pharmacogenomics, 2004, 5(3): 243-272.
  • 8Niioka T, Kagaya H, Saito M, et al. Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation[J].Int J Mol Sci, 2015, 16(1):1840-1854.
  • 9Stefanovi6 N Z, Cvetkovi6 T P, Jevtovi6-Stoimenov T M, et al. Investigation of CYP3A5 and ABCB 1 gene polymorphisms in the long- term following renal transplantation: Effects on tacrolimus exposure and kidney function[J].Exp Ther Med, 2015, 10(3): 1149 - 1156.
  • 10Kurzawski M, Da, browska J, Dziewanowski K, et al. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose- adjusted trough concentrations in kidney transplant recipients[J]. Pharmacogenomics, 2014, 15(2): 179-188.

引证文献1

二级引证文献5

检验医学与临床
2015年 第19期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部